Seeking Alpha

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...
National Institute for Health and Care Excellence

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

The evaluation committee considered evidence submitted by Takeda and a review of this submission by the external assessment group (EAG). See the committee papers for full details of the evidence.
Pharmabiz

EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma

GSK plc announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Blenrep for the treatment of adults with relapsed or ...
Business Wire

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...